This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Dermatology  • Dermatologic Disorders  • Neoplasms  • Nail Diseases  • Drug Therapy  • Adverse Effects  • Hematology/ Hematologic Malignancies  • Leukemias/ Lymphomas  • Alert me on articles by topic  Social Bookmarking   What's this?

Kyle A. Anderson, MD; Holly L. Bartell, MD; Elise A. Olsen, MD

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

We herein describe a new clinical finding of leukonychia occurring in 3 patients with mycosis fungoides (MF) being treated with vorinostat (Zolinza; Merck & Co Inc, Whitehouse Station, New Jersey), a zinc-dependent histone deacetylase (HDAC) inhibitor approved for the treatment of cutaneous T-cell lymphoma.¹

Report of Cases

Case 1

Patient 1 was a 70-year-old white woman with stage IVA MF treated previously with methotrexate, interferon alfa, bexarotene, topical nitrogen mustard, and psoralen–UV-A therapy (PUVA). She had been taking vorinostat, 300 to 400 mg/d, for 6 months when diffuse leukonychia of the fingernails was noted (Figure 1). Vorinostat treatment was discontinued after 10 months owing to persistent disease, and by 10 months later, her nails had returned to normal.

Figure appears in full text version. Figure 1. Clinical comparison of the fingernails of patient 1 after 6 months of vorinostat treatment (top, 2 hands) with normal fingernails (bottom, . . . [Full Text of this Article]

Case 2

Case 3

Comment

AUTHOR INFORMATION


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?